MedTrace Logo

Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis

NCT00282555 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2008-03-19

No results posted yet for this study

Summary

STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis. This trial aims to find out the therapeutic dose of STU-Na required for healing patients with erosive or ulcerative esophagitis. One of four dosages of STU-Na (15 mg, 30 mg, 60 mg, or 90 mg daily), or Esomeprazole 40 mg daily, an already marketed PPI, will be given to patients. The attribution to one of the 5 treatment groups will be by chance. Neither the patient nor the study physician will know, which treatment is administered to the patient.

Conditions

  • Esophagitis, Reflux

Interventions

DRUG

S-Tenatoprazole-Na (STU-Na)

Sponsors & Collaborators

  • STEBA France

    lead INDUSTRY

Principal Investigators

  • Alan Thomson, MD, Prof. · University of Alberta, Division of Gastroenterology, Department of Medicine, Edmonton, Alberta, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282555 on ClinicalTrials.gov